Lupin Q2 Net Profit Falls 22% to Rs 1,155 Crore on Exceptional Item
Lupin reported a 22.19% decline in consolidated net profit to Rs 1,155.3 crore for Q2 FY27, mainly due to an exceptional item related to an antitrust settlement of Rs 316.28 crore by its US subsidiary. Revenue rose to Rs 7,827.26 crore, supported by 9.3% growth in US sales and 14.7% growth in India sales. Total expenses increased, and the company remains the third-largest pharmaceutical player in the US generic market. Lupin also received multiple US FDA approvals and launched new products during the quarter.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (55/100). Lens Score 37/100.
Outlets measured: english, mint, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–62/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 3 Nov, 09:00 pm. Other outlets followed.